News

Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success
Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...
Medical Dialogues6h
Pfizer loses patent lawsuit to SK Bioscience over Pneumococcal Vaccine
Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...
Fierce Biotech2d
Clinical trial diversity nonprofit launches with FDA, Big Pharma vets on its board
Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...
Fierce Pharma2d
SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccine
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
BioSpace1d
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support
The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...
Fierce Biotech4d
Pfizer-backed CellCentric secures $120M for further myeloma trials
Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...
Pharm Exec4d
Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers
Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy is ...